Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Rhythm Biosciences Ltd. ( (AU:RHY) ) is now available.
Rhythm Biosciences Ltd has completed the validation of its ColoSTAT® assay and submitted a request to include it in the ISO15189 accreditation scope, paving the way for its commercialization. The ColoSTAT® test, which has shown high sensitivity and negative predictive value for colorectal cancer detection, offers a non-invasive alternative to stool-based tests and could significantly impact early cancer detection and patient management.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd (ASX: RHY) is an Australian medical diagnostics company focused on developing simple, affordable blood tests for early cancer detection. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes and reduce the global cancer burden through innovative diagnostic solutions. Rhythm collaborates with global partners to commercialize and distribute its products.
Average Trading Volume: 730,937
Technical Sentiment Signal: Buy
Current Market Cap: A$26.76M
Learn more about RHY stock on TipRanks’ Stock Analysis page.